SEP 0 4 2009 W

Form PTO-1449 Attorney's Docket No. **Application Serial No.** 10/578.692 ARR-0037-1 Applicant(s) BRMATION DISCLOSURE STATEMENT Rajiv Nayar, et al. Filing Date: **Group Art Unit:** 1652 (use several sheets if necessary) August 26, 2006 1 100 **U.S. PATENT DOCUMENTS Filing Date** Document No. Name Class Subclass Ref. No. Date Examin (if appropriate) er Initials 11/13/2003 2003/0211548 1. Packard, et al. 2. 07/25/2002 2002/0099013 Piccariello, et al. Andrianjara, et al. 3. 04/24/2003 2003/0078276 4. 04/17/2003 2003/0073217 A1 Barr, et al. 5. Bannister, et al. 04/10/2003 2003/0068280 Niven, et al. 6. 07/05/2001 2001/006939 7. 4/17/1979 4.150.071 **Pecina** 8. 4/22/1980 4,198,969 Virag 9. 3/3/1981 4,253,468 Lehmbeck 10. Craighero 11/24/1981 4,301,970 11. 6/12/1984 4,453,542 Hughes 12. 7/8/1986 4,599,311 Kawasaki 13. **Hughes** 11/4/1986 4,620,670 14. Insley, et al. 12/8/1987 4,711,848 15. Barr, et al. 03/22/1988 4,732,973 16. 06/01/1988 Brake, et al. 4,752,576 17. 10/1/1988 4,775,622 Hitzeman, et al. 18. 6/1/1989 4,837,148 Cregg Kawasaki, et al. 19. 6/1/1989 4,839,283 20. 5/1/1990 Cregg, et al. 4,929,555 21. Kawasaki, et al. 6/5/1990 4,931,373 22. Etcheverry, et al. 7/1/1990 4,940,661 23. 5,010,003 Chang, et al. 4/1/1991 24. Straus berg, et al. 5/1/1991 5,013,652 25. Lezdey,et al. 3/3/1992 5,093,316 26. 5/19/2002 5,114,953 Galardy, et al. 27. 7/28/1992 Lezdey, et al. 5,134,119 28. **Bouzidi** 9/22/1992 5,150,071 29. Lezdey, et al. 11/24/1992 5,166,134 30. Kawasaki, et al. 6/8/1993 5,218,091 31. 10/26/1993 5,256,657 Singh, et al. 32. 5,594,106 Black, et al. 1/14/1997 33. 4/8/1997 5,618,786 Roosdorp, et al.

EXAMINER:	DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Galardy

Levy, et al.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

34.

35.

12/9/1997

6/30/1998

5,696,147

5,773,438

SFP 0 1 2009 B/F

Attorney's Docket No. THE HIMATION DISCLOSURE STATEMENT **Application Serial No. Form PTO-1449** 10/578,692 ARR-0037-1 Applicant(s) Rajiv Nayar, et al. Filing Date: **Group Art Unit:** August 26, 2006 1652 (use several sheets if necessary) Lezdev, et al. 36. 07/14/1998 5,780,440 37. 4/6/1999 5,892,112 Levy, et al. 38. 7/1/1999 Heim, et al. 5,922,569 39. Seibert, et al. 10/26/1999 5,972,986 Eliamal, et al. 40. 11/30/1999 5,993,783 41. 5/30/2000 6,068,994 Barr Innis, et al. 42. 8/1/2000 6,103,500 Peterson, Jr., et al. 43. 10/17/2000 6,133,304 Hellmuth, et al. 44. 6,204,012 3/1/2001 45. Andya, et al 07/2001 6,267,958 B1 Seibert, et al. 46. 10/22/2002 6,469,040 Shapiro, et al. 47. 12/03/2002 6,489,308 B1 48. 6,544,497 Zhu, et al. 4/8/2003 49. Fritz, et al. 02/17/2004 6,693,096 50. 5/25/2004 6,740,655 Magee, et al. Kaufman C. Office Action 51. 08/27/2009 10/579.088 Kam, C.M. Office Action 52. 11/16/2007 11/077,276 Kam, C.M. Office Action 53. 07/31/2008 11/077,276 Kam, C.M. Office Action 54. 11/077,276 01/13/2009 Kam, C. M. Office Action 55. 06/05/2009 11/077,276 FOREIGN PATENT DOCUMENTS **Translation** Document No. Name Class Subclass Ref. No. Date Examin YES NO Initials EP 09/28/1988 EP 0 284 044 56. EP 0 289 336 EP 57. 11/02/1988 EP EP 0 648 838 07/31/2002 58. EP EP 1 047 450 10/02/2002 59. 07/31/2002 EP 1 226 136 ĖΡ 60. ΕP EP 73.654 A 12/27/1990 61. 06/15/2000 WO 00/34237 WO 62. WO WO 02/053138 07/11/2002 63. WO 08/22/2002 WO 02/064080 64. WO WO 02/50287 65. 06/27/2002 WO 03/068188 WO 08/21/2003 66. WO 09/18/2003 WO 03/075959 67. WO 1984/04538 WO 11/22/1984 68. 07/01/1999 WO 2004/103364 WO 69. WO 2005/003150 WO 01/13/2005

EXAMINER:	DATE CONSIDERED:
EXAMINEN.	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SEP 0 4 2009 E

o JEI	.5/							Sh	eet 1 of 1
Form PTO-1449 INFORMATION DISCLOSURE STATEMENT				Attorney's Docket No. ARR-0037-1 Application Serial No. 10/578,692					
			App	Applicant(s) Rajiv Nayar, et al.					
	luca cav	eral sheets i	f necessary)		ng Date: gust 26, 2006		Group Art U	nit:	
	71.	06/11/1992	WO 92/09282	T WO	gust 20, 2000		1 1002		1
	72.	06/11/1992	WO 92/09556	wo					
	73.	06/11/1992	WO 92/09563	wo					+
	74.	07/22/1993	WO 93/13741	wo					
	75.	02/03/1994	WO 94/02446	wo					+
	76.	09/29/1994	WO 94/21625	wo					
	77.	10/13/1994	WO 94/22309	wo					
	78.	04/13/1995	WO 95/09841	wo	· · · · · · · · · · · · · · · · · · ·				
	79.	07/27/1995	WO 95/19965	wo					
	80.	05/30/1996	WO 96/16027	wo					-
	81.	11/13/1997	WO 97/42168	WO					
	82.	2/26/1998	WO 98/07742	wo					+
	83.	04/09/1997	WO 98/14424	wo				-	+
	84.	10/8/1998	WO 98/43946	wo				-	
	85.	10/29/1998	WO 98/47863	wo					+
	86.	09/10/1999	WO 99/44989	wo					+
	00.	00/10/1000	170 007 11000						
New Assessment	L	<u> </u>	(includin	OTHE	ER DOCUMENTS title date, pertinent p	ages, etc.)			
Examin er Initials	Ref. No.	Title							
	87.	2002.	I., Handbook of Phar						
	88.	Barnes, P.J., "Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease," <i>Am.J. Respir. Crit. Care Med.</i> , 160:S72-S79, 1999. Broach, et al., "Transformation in Yeast: Development of a Hybrid Cloning Vector and Isolation of the CAN1 Gene,"							
	89.	Gene, <u>8</u> :121	-133, 1979.						
	90.	Carlson, J.A., et al., "Accumulation of PiZ α ₁ - Antitrypsin Causes Liver Damage in Transgenic Mice," J. Clin. Invest., <u>83</u> :1183-1190, 1989.							
	91.	Carpenter, J.F., et al., "Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice, Rational Design of Stable Protein Formulations Theory and Practice, <u>13</u> : 109-133, 2002.							
	92.	Carrell, R.W	., et al., Structure and	Variation	of Human Alpha 1-A	ntitrypsin," Natur	e, <u>298</u> : 329-334	, 1982.	
	93.		t al., "Improved Oligo						arch,
	94.	Churg, et al.	, "Proteases and Em	physema,	" Current Opinion in I	Pulmonary Medic	ine, <u>11</u> : 153-159	9, 2005.	
	95.	Cregg, et al.	, "Pichia Pastoris as	a Host Sy	stem for Transformat	tions," Molecular a	and Cellular Bi	ology, <u>5(12)</u> : 337	'6-3385 <u>,</u>

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of				
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).				

SEP 0 4 2009

ኤ	die (b)	Form PTO-1449	Attorney's Docket No.	Application Serial No.
Form PTO-1449 NFORMATION DISCLOSURE STATEMENT			ARR-0037-1	10/578,692
			Applicant(s)	
				Rajiv Nayar, et al.
			Filing Date:	Group Art Unit:
	(use sev	eral sheets if necessary)	August 26, 2006	1652
	96.	Das, et al., "Transformation of Kluyvo		
	97.			a lipolytica," Current Genetics, <u>10</u> : 39-48, 1985. Protein Sequence and Structure, National
	98.	Biomedical Research Foundation, 5(rioteni sequence and Sudcture, National
	99.	De Louvencourt, et al., "Transformat 154(2): 737-742, 1983.	ion of Kluyveromyces lactic by Ki	ler Plasmid DNA," Journal of Bacteriology,
	100.	du Preez, J.C., et al., "Transcriptiona Recombinant Strains of Saccharomy		
	101.	Dycaico, et al., "Neonatal Hepatitis In 1988.	duced by α ₁ - Antitrypsin: A Trans	genic Mouse Model," Science, <u>242</u> : 1409-1412,
	102.	European Search Report dated Janua		
	103.	Gadek, et al., "α ₁ - Antitrypsin Deficiency," The Metabolic Basis of Inherited Diesease, Stanbury, J.B. et al., eds., McGraw-Hill, New York, pp. 1450-1467, 1982.		
	104.	Gaillardin, et al., "Integrative transformation of the Yeast Yarrowia lipolytica," Current Genetics, <u>10</u> : 49-58, 1985.		
~	105.	Colau, B., et al., "Revised sequence of full-length complementary DNA coding for human alpha 1-antitrypsin" as disclosed (1984), GenBank Accession No. AAB59375, Host: NCBI, Database: Genbank.		
	106.	Gleeson, M.A., et al., "Transformation of the Methylotrophic Yeast Hansenula polymorpha," Journal of General Microbiology, <u>132</u> : 3459-3465, 1986.		
	107.	Hein, J "Unified Approach to Alignn	nent and Phylogenies," Methods i	n Enzymology, <u>183</u> : 626-645, 1990.
	108.	<u>128(1)</u> : 199-203, 1985.	•	eterogeneity," <i>Biochem. Biophys. Res. Comm.</i> ,
	109.	Higgins, D.G., et al., "Fast and Sensit Communications, <u>5(2)</u> : 151-153, 1989		
	110.	Hinnen, A., et al., "Transformation of		
	111.	Biotechology Prog, 17: 126-33, 2001.		1-Antitrypsin from Cultured Plant Cells,"
	112.	Cigarette Smokers," Am. Rev. Respir	² . Dis., <u>128</u> : 833-838, 1983.	ccumulation of Neutrophils in the Lungs of
	113.	168, 1983.		Cations", Journal of Bacteriology, <u>153(1)</u> : 163-
	114.			es," Interpharm Press, pp. 42-44, 261-279, 1999.
	115.	Jones, E.W., "Tackling the Protease	Problem in Saccharomyces Cerev	isiae," Methods in Enzymology, <u>194</u> : 428-453,

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Sheet 1 of 1 **Application Serial No.** Form PTO-1449 Attorney's Docket No. THEORMATION DISCLOSURE STATEMENT 10/578.692 ARR-0037-1 Applicant(s) Rajiv Nayar, et al. Filing Date: **Group Art Unit:** 1652 August 26, 2006 (use several sheets if necessary) Jones, E.W., "Vacuolar Proteases in Yeast Saccharomyces Cerevisiae," Methods in Enzymology, 85(31):372-386, 1990. Kaslow, D.C., et al., "Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose," Nature Publishing Group, 12: 494-499, 117. Kunze, et al., "Transformation of the Industrially Important Yeasts Candida maltosa and Pichia guilliermondii," Journal 118. of Basic Microbiology, 25(2): 141-144, 1984. Kurachi, K., et al., "Cloning and Sequence of cDNA Coding for α1-Antitrypsin," Proc Natl Acad Sci USA, Biochemistry, 78(11): 6826-6830, 1981. 119. Kurjan, J., et al., "Structure of a Yeast Pheromone Gene (MF α): A Putative α-Factor Precursor Contains Four Tandem 120. Copies of Mature α-Factor," Cell, 30: 933-943, 1982. Kurtz, M.B., et al., "Integrative Transformation of Candida albicans, Using a Cloned Candida ADE2 Gene," Molecular 121. and Cellular Biology, 6(1): 142-149, 1986. Ljujic, et al., "Screening of alpha-1-antitrypsin gene by denaturing gradient gel electrophoresis (DGGE)", J. Biochem. 122. Biophys. Meth., 68(3) 167-173, (2006) Lomas, D.A., et al., "The Mechanism of Z α₁-Antitrypsin Accumulation in the Liver," Nature, 357: 605-607, 1992. 123. Luisetti, et al., "Alpha-1-antitryspin deficiency 1: Epidemiology of alpha 1-antitryspin deficiency". Thorax. 59 (2): 164-124. 169, (2004) Myers, E.W., et al. "Optimal Alignments in Linear Space," CABIOS Communications, 4(1): 11-17, 1988. 125. Nail, S., et al., "Development and Manufacture of Protein Pharmaceuticals," Pharmaceutical Biotechnology, 14: 65-66, 126. Neddleman, S.B., et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of 127. Two Proteins," J. Mol. Biol., 48: 443-453, 1970. Noronha, S.B., et al., "Transition Phase in the Production of Recombinant Proteins in Yeast Under the ADH2 Promoter: An Important Step for Reproducible Manufacturing of a Malaria Transmission Blocking Vaccine Candidate," Journal of 128. Individual Microbiology & Biotechnology, 20:192-199, 1998. O'Connor, G.M., "Design and Evaluation of Control Strategies for High Cell Density Fermentations," Biotechnology and 129. Bioengineering, 39 (3):293-304, 1992. Pemberton, P., et al., "Inhaled recombinant Alpha 1-Antitrypsin Ameliorates Cigarette Smoke-Induced Emphysema in 130. the Mouse," COPD: Journal of Chronic Obstructive Pulmonary Disease, 3: 101-108, 2006. Rabe, "Outcome Measures in COPD, " Primary Care Respiratory Journal, 13: 177-178, 2004. 131. Randolph, T.W., et al., "Surfactant-Protein Interactions," Rational Design of Stable Protein Formulations: Theory and 132. Practice, Pharmaceutical Biotechnology, Kluwer Academic/Plenum Publishers, pp. 159-175, 2002. Robinson, D.F., "Comparison of Labeled Trees with Valency Three," Journal of Combinational Theory, 11: 105-133. 119,1971. Roche, N., et al., "Current Issues in the Management of Chronic Obstructive Pulmonary Diseases," Respirology, 2: 215-134. 229, 1997.

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				
*If an asterisk is placed beside the reference number, a copy is not provide PTO in a prior application that is identical in the statement and relied upon	ded because the reference was previously cited by or submitted to the			

SEP 0 4 2009

Form PTO-1449		Attorney's Docket No.	Application Serial No. 10/578,692		
THAT PINATION PRODUCTION OF STATEMENT		ARR-0037-1	10/370,092		
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Rajiv Nayar, et al.			
		Filing Date:	Group Art Unit:		
(use se	veral sheets if necessary)	August 26, 2006	1652		
135.	1 00		Hansenula polymorpha by Autonomous 1986.		
136.	<u>312</u> : 77-80, 1984.		tant Mutant of Human Alpha1-Antitrypsin," <i>Nature</i> ,		
137.	Saccharomyces Cervisiae," Bio/Tec	hnology, <u>7</u> : 705-709, 1989.	Chimeric Ubiquitin Fusion Proteins in		
138.	Biology and Evolution, pp. 406-425,	1987.	econstructing Phylogenetic Trees," Molecular		
139.	Potency Provides Further Support f 479, 1991.	or the Functional Equivalence Hy	Serine Proteases – Significant Increase in Inhibitor pothesis," <i>Molecular Immunology</i> , 28(1/2): 472-		
140.	Current Genetics, <u>16</u> : 339-346, 1989.		Using Single Stranded Nucleic Acids as a Carrier,"		
141.	Medicine, 21(4):621-632, 2000.	Shapiro, "Envolving Concepts in the Pathogenesis of Chronic Obstructive Pulmonary Disease," <i>Clinics in Chest Medicine</i> , 21(4):621-632, 2000.			
142.		Smith, et al., "Pulmonary Deposition and Clearance of Aerosolized Alpha-1-Proteinase Inhibitor Administered to Dogs and to Sheep," J. Clin, Invest., <u>84</u> : 1145-1154, 1989.			
143.					
144	An Integrated Analysis," European	Respiratory Society, Abstract, 200			
145.	2007.	Stolk, et al., "Progression Parameters for Emphysema: A Clinical Investigation," <i>Respiratory Medicine</i> , <u>101</u> : 1924-1930, 2007.			
146	Biotechnol., <u>52</u> : 516-523, 1999.	Terashima, et al., "Production of Functional Human Alpha1-Antitrypsin by Plant Cell Culture," <i>Appl. Microbiol. Biotechnol.</i> , <u>52</u> : 516-523, 1999.			
147	Travis, et al., "Isolation and Properties of Recombinant DNA Produced Variants of Human Alpha1-Proteinase Inhibitor," Journal of Biological Cheimstry, <u>260(7)</u> : 4384-4389, 1985.				
148.	Tuite, M.F., et al., "Regulated High Efficiency Expression of Human Interferon-Alpha in Saccharomyces cerevisiae," The EMBO Journal, 1(5): 603-608, 1982.				
149.	Van Den Berg, et al., "Kluyveromyces as a Host of Herterologous Gene Expression: Expression and Secretion of Prochymosin", Biotechnology, 8: 135-140, 1990.				
150.		sin deficiency: an overview, Acta.	. Clin. Belg., 48(3): 171-189, (1993)		
151.	Gene, <u>34</u> : 315-323, 1985.	Wells, J.A., "Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites, et al., Gene, 34: 315-323, 1985.			
152	Wells, J.A., et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Sutilisin, Philos Trans. R. Soc. London, 317: 415-423, 1986.				
153	Wilbur, W.J., et al., "Rapid Similarity	Searches of Nucliec Acid and Pr	otein Data Banks," Proc Natl Acad of Sci USA, <u>80</u> :		

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).				

SEP 0 4 2009 W

Application Serial No. Attorney's Docket No. **Form PTO-1449** 10/578,692 ARR-0037-1 INFORMATION DISCLOSURE STATEMENT Applicant(s) Rajiv Nayar, et al. **Group Art Unit:** Filing Date: 1652 August 26, 2006 (use several sheets if necessary) 726-730, 1983. Winkler, M., "Time-Profiling and Environmental Design in Computer -Controlled Fermentation and Enzyme Production," Genetically-Engineered Proteins and Enzymes from Yeast: Production Control, Ellis Horwood Limited, Chp. 4 and 5, pp. 154. Wu, Y., et al., "A Lag in Intracellular Degradation of Mutant α1-Antitrypsin Correlates with the Liver Disease Phenotype 155. in Homogygous PiZZ α1-Antitrypsin Deficiency," Proc. Natl. Acad. Sci., 91: 9014-9018, 1994. Zakian, V.A., et al., "Construction, Replication, and Chromatin Structure of TRP1 R1 Circle, a Multiple-Copy Synthetic Plasmid Derived from Saccharomyces cerevisiae Chromosomal DNA", Molecular and Cellular Biology, 2(3): 221-232, 156. 1982. Zoller, et al., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in any Fragment of DNA," Nucleic Acids Research, 10(20): 6487-6500, 1982. 157. Zou, et al., "Maspin, a Serpin with Tumor-Suppressing Activity in Human Mamary Epithelial Cells," Science, 263: 526-158. 529, 1994.

EXAMINER:	DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).